Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Mesothelioma 1Melanoma 1Kidney Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 9Nivolumab 5tislelizumab 2spartalizumab 2belinostat 2atezolizumab 2Pemetrexed 2Paclitaxel 2Ipilimumab 2Fluorodeoxyglucose F18 2Docetaxel 2Cisplatin 2tocilizumab 1sargramostim 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1epacadostat 1enzalutamide 1durvalumab 1cabozantinib 1bosutinib 1Sorafenib 1Sirolimus 1Quality of Life 1Plicamycin 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × CB-839 × Genitourinary × Clear all
NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡